Brief report| Volume 22, ISSUE 5, P657-659, May 1987

A controlled trial of methylene blue in severe depressive illness

      This paper is only available as a PDF. To read, Please Download here.


      Methylene blue, 15 mg/day, was compared with placebo in treatment of severe depressive illness. The 3-week trial was designed to avoid bias by placebo response and also to avoid observer bias. Improvement in patients receiving methylene blue was significantly greater than in those receiving placebo. Methylene blue at a dose of 15 mg/day appears to be a potent antidepressant, and further clinical evaluation is essential.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Beck AT
        • Ward CH
        • Mendelson M
        • Mock J
        • Erbaugh J
        An inventory for measuring depression.
        Arch Gen Psychiatry. 1961; 4: 561-569
        • Feighner J
        • Robins E
        • Guze S
        • Woodruff R
        • Winokur G
        • Munoz R
        Diagnostic criteria for use in psychiatric research.
        Arch Gen Psychiatry. 1972; 26: 57-63
        • Hamilton M
        Development of a rating scale for primary depressive illness.
        Br J Soc Clin Psychol. 1976; 6: 278-296
        • Montgomery SA
        • Asberg MA
        A new depression scale designed to be sensitive to change.
        Br J Psychiatry. 1979; 134: 382-389
        • Naylor GJ
        Vanadium and affective disorders.
        in: Gabay GS Harris J Ho BT Metal Ions in Neurology and Psychiatry. Alan R. Liss, New York1985: 91-105
        • Naylor GJ
        • Dick DAT
        • Johnston BB
        • Hopwood SE
        • Dick EG
        • Smith AHW
        • Kay D
        Possible explanation for therapeutic action of lithium and a possible substitute (methylene blue).
        Lancet. 1981; ii: 1175-1176
        • Naylor GJ
        • Smith AHW
        • Trotter P
        Catalysis of the reduction of vanadate by psychotropic drugs.
        Neuropharmacology. 1983; 22: 653-656
        • Naylor GJ
        • Martin B
        • Hopwood SE
        • Watson Y
        A two-year double-blind crossover trial of the prophylactic effect of methylene blue in manic-depressive psychosis.
        Biol Psychiatry. 1986; 21: 915-920